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Abstract: The functions of non-coding microRNAs (miRNAs) in tumorigenesis are just beginning to emerge. Previous 
studies from our laboratory have identiﬁ  ed a number of miRNAs that were deregulated in colon cancer cell lines due to the 
deletion of the p53 tumor suppressor gene. In this study, the in vivo signiﬁ  cance of some of these miRNAs was further 
evaluated using colorectal clinical samples. Ten miRNAs (hsa-let-7b, hsa-let-7g, hsa-miR-15b, hsa-miR-181b, hsa-miR-191, 
hsa-miR-200c, hsa-miR-26a, hsa-miR-27a, hsa-miR-30a-5p and hsa-miR-30c) were evaluated for their potential prognostic 
value in colorectal cancer patients. Forty eight snap frozen clinical colorectal samples (24 colorectal cancer and 24 paired 
normal patient samples) with detailed clinical follow-up information were selected . The expression levels of 10 miRNAs 
were quantiﬁ  ed via qRT-PCR analysis. The statistical signiﬁ  cance of these markers for disease prognosis was evaluated 
using a two tailed paired Wilcoxon test. A Kaplan-Meier survival curve was generated followed by performing a Logrank 
test. Among the ten miRNAs, hsa-miR-15b (p = 0.0278), hsa-miR-181b (p = 0.0002), hsa-miR-191 (p = 0.0264) and
hsa-miR-200c (p = 0.0017) were signiﬁ  cantly over-expressed in tumors compared to normal colorectal samples. Kaplan-
Meier survival analysis indicated that hsa-miR-200c was signiﬁ  cantly associated with patient survival (p = 0.0122). The 
patients (n = 15) with higher hsa-miR-200c expression had a shorter survival time (median survival = 26 months) compared 
to patients (n = 9) with lower expression (median survival = 38 months). Sequencing analysis revealed that hsa-miR-181b 
(p = 0.0098) and hsa-miR-200c (p = 0.0322) expression were strongly associated with the mutation status of the p53 tumor 
suppressor gene. Some of these miRNAs may function as oncogenes due to their over-expression in tumors. hsa-miR-200c 
may be a potential novel prognostic factor in colorectal cancer.
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Introduction
microRNAs (miRNAs) are non-coding, single-stranded RNAs of ~22 nucleotides, derived from miRNA 
duplex complexes processed from larger pre-miRNAs by the RNase III enzyme Dicer (Bartel, 2004). 
One strand of this duplex can associate with the RNA-induced silencing complex (RISC), while the 
other strand is generally degraded by cellular nucleases. The miRNA-RISC complex has been shown 
to bind to speciﬁ  c mRNA targets and cause the translational repression or cleavage of these mRNA 
sequences. Currently, there are several hundred miRNAs that have been identiﬁ  ed (Esquela-Kerscher 
and Slack, 2006). Although miRNA-mediated mRNA degradation occurs in mammals, most miRNAs 
are thought to use a second mechanism of gene regulation via imperfect base-pairing to the 3’-untrans-
lated regions (3’-UTRs) of their mRNA targets. This results in the repression of target gene expression 
post-transcriptionally, likely at the translational level of gene expression (Lee et al. 1993; Wienholds 
and Plasterk, 2005). Recent studies from our laboratory as well as those of other groups have shown 
that the expression of miRNAs is important in colorectal and other types of cancer (Benard and Douc-
Rasy, 2005; Bottoni et al. 2005; Calin et al. 2002; Calin et al. 2005; Cimmino et al. 2005; Cummins
et al. 2006; Xi et al. 2006). miRNA regulates gene expression at the post-transcriptional level by perfect 
or imperfect base pairing with many target mRNA transcripts (Chen and Meister, 2005; Mattick and 
Makunin, 2005). This provides cells with acute and energy efﬁ  cient controls to mediate gene expression 
in response to cellular stresses such as drug treatment. Translation control plays a key role in the 
mechanism of cellular resistance to anti-cancer drug treatment (Chu et al. 1999; Chu et al. 1991;
Fu et al. 1996; Ju et al. 2003; Ju et al. 1999; Mosner et al. 1995). Therefore, it is crucial to understand 
the roles and regulatory mechanisms of translational control in chemoresistance, and in particular, the 
roles of miRNAs as translational regulators.
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At present, over 300 mammalian miRNAs have 
been identiﬁ  ed and some of them have been shown 
to play important roles in the regulation of cell 
differentiation, proliferation and apoptosis. Each 
individual miRNA can potential regulate mRNA 
translation for up to several hundred genes via 
imperfect base pairing based on bioinformatic 
analysis (Krek et al. 2005). We reasoned that 
miRNAs may be a better class of biomarkers 
because of their broad regulatory functions and the 
ability to measure their expression levels with far 
better accuracy than is currently achievable for the 
mRNAs themselves (Draghici et al. 2006).
Studies from our group have demonstrated that 
p53, in addition to regulating gene expression as 
a transcription factor, may exert its tumor 
suppressor gene function by mediating miRNA 
expression in a colon cancer model (Xi et al. 2006). 
Over 46% of miRNA promoters contain putative 
p53 consensus binding site(s). A number of 
miRNAs were discovered to be deregulated due to 
the loss of the p53 tumor suppressor in colon cancer 
cell lines. Some of these miRNAs mediate key 
mRNA targets such as Ras, E2F5, c-myc, eIF5A, 
and PP2B. These genes have been shown to be key 
factors in inﬂ  uencing cell cycle control and chemo-
sensitivity (Banerjee et al. 1998; Liu et al. 1989; 
Sinha et al. 1995). A recent study examined miRNA 
expression in 16 colon cancer cell lines and
12-matched-pair tumor and non-tumor tissues 
using the real time qRT-PCR approach (Bandres 
et al. 2006). In this report, among 156 miRNAs 
analyzed, six were found to be signiﬁ  cantly altered 
and miR-31 was correlated with tumor staging.
Instead of random screening, we decided to use 
a rationalized approach based on our expression 
proﬁ  ling analysis of HCT-116 (wt-p53) and HCT-
116 (null-p53) colon cancer cell lines (Xi et al. 
2006) to further evaluate the in vivo signiﬁ  cance 
of deregulated miRNAs in relation to chemosen-
sitivity. In the current study, the expression levels 
of ten miRNAs (hsa-miR-30a-5p, hsa-miR-181b, 
hsa-let-7g, hsa-miR-26a, hsa-let-7b, has-miR-15b, 
has-miR-27a, has-miR-200c, has-miR-191, and 
has-miR-30c) were investigated to evaluate their 
clinical relevance in colorectal cancer. 24 normal 
and paired colorectal cancer specimens were 
selected as a model for this investigation. These 
ten miRNAs were chosen based on their high 
expression levels in tumors displaying p53 dele-
tion, their relationship with p53 and their predicted 
target mRNAs (e.g. cytochrome C, ECIP-1, 
MAPPKKK1, TEM6, E2F5, GATA6, PP2B, and 
eIF5A). Based on our results, some of these 
miRNAs may function as oncogenes due to their 
overexpression in tumors. hsa-miR-200c is a poten-
tial novel prognostic factor for survival of patients 
with colorectal cancer. Overexpression of these 
miRNAs may be due to the loss of p53 tumor 
suppressor function in tumors.
Patients and Methods
Patients and Samples
A total of 48 snap frozen colorectal patient biopsy 
specimens were selected (24 paired normal and 
tumor specimens). These patients had undergone 
surgical resection of primary colorectal adenocar-
cinoma at the Department of General Surgery, 
University of Ulm, Germany. Patient consent forms 
were obtained from every patient according to the 
institutional regulations. The characteristics of these 
patients are shown in Table 1. Some were treated 
with adjuvant 5-FU based chemotherapy and others 
were treated with palliative high-dose 5-FU/FA.
RNA Isolation and cDNA synthesis
Total RNAs were isolated using a previously 
published protocol (Ju et al. 2003). In brief, TRIzol 
reagent (Invitrogen, CA) was used to isolate total 
RNA from snap frozen tissues. RNA was treated 
with DNase I (Promega, WI). The integrity of total 
RNA was determined by 1% formaldehyde-agarose 
gel electrophoresis. cDNA synthesis was carried 
out with the Superscript III cDNA synthesis kit 
(Invitrogen, CA) using 1 µg of total RNA as the 
template and speciﬁ  c reverse primers (Supplemen-
tary Table) under 65°C, 5 min, and 50°C, 60 min 
of reverse transcription. A total of three fragments 
were synthesized for further analysis.
Mutation Detection of p53 
by PCR and Sequencing
The PCR reaction was carried out in a 25 µl reac-
tion mixture containing cDNA 2 µl, 10x PCR golden 
buffer 2.5 µl, 1.5 mM MgCl2, 200 µM dNTP 
(Ambion, TX), 5 pmol primers and 1.25 U of 
AmpliTAq Gold polymerase plus 1M betaine 
(Sigma, MI). All PCR reagents were from Applied 
Biosystems Inc. except where mentioned. The 
reaction was initiated at 95°C for 10 min. Thermal 
cycling was as follows: denaturation at 95°C for 
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30 sec, annealing using touchdown from 62°C to 
55°C for 30 sec (0.5°C decrement each round), 
extension at 72°C for 35 sec followed by an addi-
tional 25 rounds of 95°C 30 sec, 55°C 30 sec and 
72°C 40 sec. Final extension was carried out at 
72°C for 10 min on the PTC-225 Peltier Thermal 
Cycler (Bio-Rad, MA). PCR products were puri-
fied using a MultiScreen-PCR purifying plate 
(Millipore, MA) and submitted for sequencing. 
The PCR and sequencing primers were designed 
with Primer Premier (version 5.0) software 
(PREMIER Biosoft International, CA) and are 
listed in the Supplementary Table. Sequencing was 
performed with the BigDye Terminator v3.1 Cycle 
Sequencing Kit from Applied Biosystems, Inc. 
(CA). Five microliters (50 ng) of template DNA 
was added to wells of a 96-well plate containing 
15 μl of sequencing cocktail consisting of 0.4 μl 
premix from sequencing kit, 7.6 µl 2.5 × sequencing 
buffer, 0.5 µl 10 mM primer and 6.5 µl water. 
Sequencing reactions were carried out for 35 cycles 
(96°C, 10 sec; 50°C, 5 sec; 60°C, 2 min 30 sec). 
The products were precipitated with 50 μl 100% 
ethanol and 2 μl 3M NaOAc (pH 4.8), and pellets 
were rinsed with 70% ethanol. After addition of 
10 μl Hi-Di Formamide (Applied Biosystems Inc, 
CA) and denaturing at 94°C for 10 min, samples 
were loaded onto an ABI 3730xl sequencer. 
Sequences were analyzed with SeqManII from 
DNASTAR, Inc. by comparing with Homo sapiens 
tumor protein p53 mRNA sequence (NM_000546). 
All allelic variations were recorded.
miRNA Reverse Transcription 
and qRT-PCR Analysis
mirVana™ qRT-PCR Primer Sets (Ambion Inc. TX) 
for miRNA speciﬁ  c reverse transcription including 
hsa-miR-30a-5p, hsa-miR-181b, hsa-let-7g, hsa-
miR-26a, hsa-let-7b, has-miR-15b, has-miR-27a, 
has-miR-200c, has-miR-191, has-miR-30c, and 
endogenous control 5S rRNA were utilized 
according to the manufacture’s protocol. Brieﬂ  y, 
the reaction master mix containing mirVana™
5 × RT Buffer, 1 × mirVana™ RT Primer, Array-
Script™ Enzyme Mix and nuclease-free water was 
mixed with 20 ng of each total RNA sample. These 
mixtures were incubated for 30 min at 37°C, then 
10 min at 95°C. qRT-PCR was carried out using 
the Applied Biosystems 7500 Real-Time PCR 
System (Applied Biosystems Inc. CA) and 
mirVana™ qRT-PCR miRNA Detection Kit 
Table 1. Clinical features of the 24 patients in the series used in this study.
Characteristics Frequency  Percentage  (%)
Age(Years)    
 Mean(range)  62(30-93) 
Gender    
 Male    14  58.3
 Female  10  41.7
Anatomic site    
 Ascending  colon  3  12.5
  Transverse colon   2  8.3
 Descending  colon  4  16.7
 Sigmoid  colon  3  12.5
 Rectum  12  50.0
Histology    
 Adenocarcinoma    24  100
UICC stage    
 I  4  16.7
 II  4  16.7
 III  8  33.3
 IV  8  33.3
Survival (Months)    
 Mean(range)  30(0-75)   
 0-20  3  12.5
 20-50  20  83.3
 >50  1  4.2
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(Ambion Inc. TX). The PCR master mix containing 
mirVana™ 5 × PCR Buffer (with SYBR® Green I), 
50 × ROX, SuperTaq™ Polymerase, mirVana™ 
PCR Primers, and RT products was processed as 
follows: 95˚C for 3 min, and then 95˚C for 15 sec, 
60˚C for 35 sec for up to 40 cycles (n = 3). Signal 
was collected at the endpoint of every cycle.
Statistical Analysis
The gene expression ∆CT values of miRNAs from 
each sample were calculated by normalizing with 
internal control 5S rRNA and relative quantitation 
values were plotted using SDS software v1.2 
(Applied Biosystems Inc. CA). The statistical 
studies were performed using MedCalc® for 
Windows, version 7.4.2.0 (MedCalc software, 
Belgium). The statistically signiﬁ  cant differences 
in expression level between tumor and normal 
tissues for each target were calculated using a 
paired Wilcoxon test. The Logrank test for the 
generated Kaplan-Meier curve was conducted to 
evaluate the association between the expression 
level of each miRNA and survival rate. The cut-off 
was set to p <0.05.
Results
Overexpression of miRNAs 
in Colorectal Cancer
In this study, the expression levels of 10 different 
miRNAs known to be deregulated based on our 
previous studies were quantiﬁ  ed using miRNA 
speciﬁ  c qRT-PCR analysis. Among these, four 
miRNAs were found to be overexpressed in 
colorectal cancer samples. The expression of hsa-
miR-15b was overexpressed by nearly 1.5-fold 
(Median: 1.30 vs. 0.89, p = 0.0278) (Figure 1A). The 
expression of hsa-miR-181b was elevated 2.5-fold 
(Median: 1.54 vs. 0.61, p = 0.0002) in tumor samples 
(Figure 2). The expression of hsa-miR-191 was 
signiﬁ  cantly enhanced 1.4-fold (Median: 1.44 vs. 
1.01, p = 0.0264) in colorectal tumors (Figure 1C). 
The expression of hsa-miR-200c was also signiﬁ  -
cantly upregulated 3-fold in tumor specimens 
(Median: 2.25 vs. 0.75, p = 0.0017) (Figure 1D).
Evaluation of Prognostic Values 
of miRNAs
To further evaluate the clinical relevance of these 
overexpressed miRNAs in colorectal cancer in 
terms of prognosis, Kaplan-Meier survival analysis 
was performed using patient overall survival. Our 
results indicated that hsa-miR-200c was signiﬁ  -
cantly associated with patient survival (Figure 2). 
Patients (n = 9) with low expression of hsa-miR-
200c (∆CT less than 4.54) tended to have longer 
survival (median survival of 38 months vs. 26 
months) than patients (n = 15) with higher levels 
of hsa-miR-200c expression (p = 0.00122). The 
expression of hsa-miR-200c was not related to the 
difference in tumor stage (data not show).
Correlation of p53 Status 
and miRNA expression
Our previous studies showed that over 46% of the 
putative promoter sites of 324 miRNAs contain 
p53 binding site(s). We thus decided to sequence 
the p53 gene’s coding sequence in all 48 patient 
samples. It turned out that over 46% of colorectal 
tumors contained p53 mutations or deletions
(Table 2). Representative p53 sequence traces 
around the mutation and deletion regions are illus-
trated in Figure 3. The expression of hsa-miR-181b 
was 3.4-fold higher in 11 tumors with p53 muta-
tions/deletions than the corresponding normal 
samples with wild type p53 and was strongly asso-
ciated with p53 mutation status (median: 1.72 vs. 
0.50, p = 0.0098) (Figure 4A). The expression of 
hsa-miR-200c was 2.5-fold higher in the 11 tumors 
containing p53 deletions/mutations than the corre-
sponding counterparts and was also strongly asso-
ciated with the p53 mutation status (median: 2.20 
vs. 0.87, p = 0.03) (Figure 4B). We also compared 
the expression status of miRNAs within the tumors 
with or without p53 mutations. The results also 
showed a signiﬁ  cant correlation of hsa-miR-200c 
and hsa-miR-181b with p53 mutation status
(data not show). Both of these miRNAs contain 
p53 binding site(s) in the putative promoter 
regions.
Discussion
Many recent efforts in the ﬁ  eld of cancer research 
have focused on miRNA biology. Even a small 
change in miRNA expression can cause a profound 
effect on the gene expression of hundreds of 
mRNAs at the post-transcriptional or translational 
level. Mounting evidence has shown that miRNAs 
are involved in cancers such as lymphoblastic 
leukemia, glioblastoma, B-cell chronic lympho-
cytic leukemia (B-CLL), and many solid tumors 
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including colon cancer (Benard and Douc-Rasy, 
2005; Calin et al. 2004; Cimmino et al. 2005; 
Cummins et al. 2006).
Previous studies from our group have identiﬁ  ed 
many deregulated miRNAs associated with the p53 
tumor suppressor gene (Xi et al. 2006). As a tran-
scription factor, p53 regulates its downstream genes 
to mediate cell cycle control and apoptosis (Bunz 
et al. 1998; Bunz et al. 1999; Wang et al. 2001; Yu 
et al. 2002). We provided evidence that p53 may 
also act as a tumor suppressor by regulating certain 
miRNAs (Xi et al. 2006). p53 is one of the most 
frequent mutated tumor suppressor genes in 
colorectal and other cancer types (Hollstein et al. 
1991). In this study, we further investigated the 
clinical relevance of some of the miRNAs overex-
pressed due to the loss of p53 in colorectal cancer. 
These overexpressed miRNAs may be involved in 
the oncogenic process.
We chose 24 paired normal colon tissues and 
cancer specimens for the expression analysis of 10 
miRNAs. This is a valid set of clinical samples with 
which to evaluate the clinical relevance of miRNAs 
in colorectal cancer. The sample size is small, but 
unlike mRNA marker discovery starting from over 
40,000 genes, which may need at least 100 samples 
to obtain reliable markers, there are only a few 
hundred known miRNAs in mammals. Therefore, 
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Figure 1. miRNA expression in colorectal cancer and normal tissue specimens. Gene expression values were expressed as ratios between 
miRNAs with an internal control 5S ribosomal gene. (A) hsa-miR-15b expression (p = 0.0278). (B) hsa-miR-181b expression (p = 0.0002). 
(C) hsa-miR-191 expression (p = 0.0264). (D) hsa-miR-200c expression (p = 0.0017). The statistical signiﬁ  cance was evaluated by a two 
tailed paired Wilcoxon test. The small charts in the upper right corners display the miRNA expression for all individual paired samples
(24 Tumors vs. Normal Samples). 
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Figure 2. Kaplan-Meier overall survival curve based on hsa-miR-200c expression (p = 0.0122, Logrank test).
we are working with up to 100-fold less marker 
candidates compared to mRNA transcript proﬁ  ling. 
This is in fact a major advantage of using miRNAs 
as potential biomarkers instead of mRNAs. Another 
advantage is that each miRNA can potentially 
regulate several hundred genes at the post-transcrip-
tional level. Proﬁ  ling these master regulators may 
be superior to proﬁ  ling their downstream mRNA 
targets. Four of the ten miRNAs were overex-
pressed in colorectal cancer samples (Figure 1). 
These results have been further confirmed in 
another study by our group (manuscript under 
review) and others (Cummins et al. 2006). Each of 
these miRNAs is capable of potentially regulating 
well over 100 target mRNAs via imperfect base 
pairing. Some of these miRNAs have recently been 
reported to function as potential oncogenes 
(Hammond, 2006). The hsa-miR-200c is strongly 
associated with overall patient survival (Figure 2). 
hsa-miR-200c can potentially regulate over 200 
target genes including MAPKKK3, eIF-4E, RAS 
homologs, RNA polymerase II, and cyclin L1 based 
on bioinformatics analysis (John et al. 2004). Thus, 
in some way, miRNAs can be viewed as master 
regulators. This study may provide some candidate 
miRNAs as potential targets for new therapeutics 
development. The detailed molecular and cellular 
mechanisms underlining the action of these 
miRNAs will be investigated in our future 
studies.
The p53 status in these samples was determined 
via sequencing of the p53 cDNAs (Figure 3 and 
Table 2). Nearly 50% of the tumors contained p53 
mutations/deletions and this was highly consistent 
with many previous reports that p53 is one of the 
most frequently mutated tumor suppressor genes 
in cancer (Tomita et al. 1999). Among the tumors 
with mutated p53, both hsa-miR-181b (Figure 4A) 
and hsa-miR-200c (Figure 4B) were highly over-
expressed compared to the paired normal samples. 
This is consistent with our previous report that p53 
may potentially mediate miRNA expression to exert 
its tumor suppressor function. The loss of p53 tumor 
suppressor function will activate some of these 
potential oncogenic miRNAs. Many genes such as 
cytochrome C, ECIP-1, MAPPKKK1, TEM6, E2F5, 
GATA6, PP2B, and eIF5A, are predicted to be 
regulated by hsa-miR-181b. These genes have been 
shown to be important for cell signaling, cell cycle 
control and chemosensitivity. We speculate that the 
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Table 2. p53 mutations conﬁ  rmed by cDNA sequencing in all samples.
# Sample  cDNA-position  Normal  Tumor  Normal  Tumor
1 15 720  GTC  TTC Leu  Ser
2 25 766 GTT/GAT GAT Val/Asp  Asp
3 09 775  CGC CAG Arg  Gln
4 26 829  CAT CGT His  Arg
5 07 835  ATC ACC Ile  Thr
6 12 859  GTG GTG/GAG Val  Val/Glu
7 13 984  GGC   AGC Gly  Ser
8 29 984  GGC  AGC Gly  Ser
9 22  1084  CCT CTT Pro  Leu
10 23  1167  CGA  CGA/TGA Arg Arg/Ter(Stop)
11  17  626-646               Deletion
G C G T CCG
G C TTCCG
15N
15T
GGWT G T
GGA T G T
25N
25T
G G C G C T G
G G C A C T G
09N
09T
S C A T C T
G C G T C T
26N
26T
TTA CCC
TTA T CC 07N
07T
12N
12T
G T G T GG
G T GWGG
13N
13T GGC A G C
GGC GGC G G C GGC
GGC A G
29N
29T
T CCT GG
t c c t g g 22N
22T T C TTGG
23N
23T
A G C G A G
A GYGA G
17N
17T
Figure 3. Sequence analysis of p53 cDNA. A total of 11 samples have p53 mutations/deletion in the coding region. Numbers refer to
individual patients. N = normal; T = tumor tissue.
miRNAs can modulate expression of a number of 
genes at the translational level.
In conclusion, in this study, the in vivo signiﬁ  cance 
of 10 mature miRNAs was evaluated in 24 matched 
normal and colorectal cancer patient samples.
The expression of hsa-miR-15b, hsa-miR-181b, 
hsa-miR-191 and hsa-miR-200c were signiﬁ  cantly 
over-expressed in colorectal cancer patients and 
they may be associated with the development of 
the disease. The expression of hsa-miR-200c was 
strongly associated with overall patient survival. 
That expression of hsa-miR-200c was not related 
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to the different stages of the disease further 
supports this notion. We believe that this is just the 
beginning of trying to understand how miRNAs 
(the micrornanome) are involved in colorectal and 
perhaps other cancers. Large follow up studies will 
be necessary in the near future to further conﬁ  rm 
the signiﬁ  cance of these miRNA markers. Modula-
tion of miRNAs will likely be a new frontier for 
cancer diagnosis and treatment (Hampton, 
2005).
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Supplementary Table 
Primer sets used for RT, PCR ampliﬁ  cation and sequencing of p53 gene.
Fragments Primers  Lengths  Range
1 F
a: AAGTCTAGAGCCACCGTCCA  439  From+115 to +553
 R
a: TCTGGGAAGGGACAGAAGA
  
2  F: GAAGACCCAGGTCCAGATGA  643  From+417 to +1059
 R:  AGCTGTTCCGTCCCAGTAGA
  
3  F: CCATCCTCACCATCATCACA  528  From+1000 to +1527
 R:  GCAAGCAAGGGTTCAAAGAC
aF and R refer to forward and reverse primers, respectively.
Both forward and reverse primers were used for sequencing. Reverse primer was used for reverse transcription reaction.
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